Genedata today announced that Genedata Screener has been enhanced towards full automation of the planning, execution, and data analysis of screening experiments.
Leading platform for screening data analysis delivers new capabilities for real-time analysis and direct data imports to a research data warehouse
BASEL, Switzerland (PRWEB) January 09, 2018
Genedata, a leading provider of advanced software solutions for R&D, today announced that Genedata Screener® has been enhanced towards full automation of the planning, execution, and data analysis of screening experiments. The Screener platform is relied on by leading pharmaceutical companies, CROs, and academic research institutions around the world for processing, standardizing and integrating their data from all types of screens - including complex and ultra-high throughput experiments – and funneling results into their data warehouse. This process is now fully automated by Genedata Screener to significantly streamline screening data analysis and increase lab productivity, also through the integration of HighRes Biosolutions Cellario with Screener. New automation capabilities and the Cellario integration will be showcased at SLAS2018 (Genedata Booth #1141, HighRes Booth #905; Feb. 3-7, San Diego Convention Center).
Advanced Automation Fuels Novel Drug Discovery
Increasing automation of lab operations and research processes expedites screening campaigns and reduces lead optimization cycle times in drug discovery. At SLAS2018, Genedata will demonstrate a host of new automation features in Genedata Screener including:
- Real-time Tracking of screening experiments using user-defined QC criteria: Scientists can produce and monitor results while an experiment is running; email alerts are issued if experiment results fall outside of expected values; and overview dashboards improve experiment quality.
- Automated Sessions connect laboratory automation with automated data analysis, based on pre-defined, user-configurable processing methods and business rules. Out-of-the-box, these sessions fully automate analysis - from experiment data upload to the transfer of end results to the data warehouse with zero manual handling.
- Integration with Cellario lab automation software combines these new Screener functionalities for use with one of the most advanced robotic systems, enabling real-time data analysis as results from HighRes Cellario are immediately analyzed in Genedata Screener.
Genedata Screener’s new automation capabilities are amplified by the Genedata/HighRes Biosolutions partnership that “effectively accelerates and standardizes data analysis of screening experiments,” noted Ira Hoffman, president of HighRes Biosolutions. “The integration of Cellario with Genedata Screener saves scientists’ precious time as experiment results are automatically available in Screener immediately after an experiment is completed. Moreover, combining the two solutions brings consistent support of real-time analysis to the automation world.”
“Genedata is committed to increasing productivity by continually improving workflow automation aimed at eliminating the mundane,” said Dr. Othmar Pfannes, CEO of Genedata. “By partnering with HighRes, a leader in lab automation technology, we are taking the next step in effectively raising the bar on automating screening processes and creating new levels of efficiency, which will help our customers to contain the costs of novel drug discovery.”
About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US. http://www.genedata.com.
Follow Genedata on LinkedIn
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
